Abstract 166P
Background
Genomic tests designed to facilitate decisions about treatment management include those that identify alterations in single genes and multimarker tumor panels. Multimarker panels include targeted gene-expression profiling tests that are used to estimate prognosis and/or the likelihood of recurrence. Currently, there are no nationally representative data describing oncologists’ awareness, knowledge, and use of NGS testing to inform patient care, especially in community practice settings. The purpose of this study was to investigate how oncologists in the Pakistan use NGS tests to evaluate patients with cancer and inform treatment recommendations.
Methods
This study was performed retrospectively on 73 biopsy specimens received for histopathological workup at the Aga Khan University Hospital. The specimens were obtained between January 2021 and December 2022. The diagnosis of malignancy was confirmed based on histpathochemical features. Briefly, DNA from FFPE tissues were extracted and tested through TruSight Tumor 15 (TST15) targeted cancer gene panel to detect variants in 15 genes associated with solid tumors using High throughput DNA sequencing; next-generation sequencing (NGS) technology to sequence DNA on Illumina, Miseq Insturment.
Results
Out of 73 patients tested, 28 (38.3%) were females and 45 (61.6%) were males with a median age of 52 years and patients’ ages ranged from 20 years to 84 years. The histopathological diagnosis were inclusive of 7 cancer types (Lung, Melanoma, Breast, Colon, Ovarian, Gastric, and Prostate. All samples underwent targeted analysis of tumor mutations to check for the presence of somatic gene variants. The outcome demonstrated no mutation in 14 (19.17%) patients, whereas, 59 (80.8%) tested positive with mutations in 7 of the 15 targeted genes such as TP53 (54.7%), KRAS (27%), EGFR (12%), PIK3CA (10.9%), ERBB2 OR HER2 (5.5%), NRAS (4%), MET (1%) and BRAF (1%).
Conclusions
NGS testing is changing the paradigm for molecular testing in these patients, with time, it should be possible to apply NGS to routine diagnostics. More research is needed to establish the clinical usefulness of these tests, to develop evidence-based clinical guidelines for their use in practice.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract